TY - JOUR
T1 - COVID-19 manifestations in people with Parkinson’s disease
T2 - a USA cohort
AU - Xu, Yaqian
AU - Surface, Matthew
AU - Chan, Amanda K.
AU - Halpern, Joshua
AU - Vanegas-Arroyave, Nora
AU - Ford, Blair
AU - Feeney, Megan P.
AU - Kwei, Kimberly T.
AU - Katus, Linn E.
AU - Kuo, Sheng Han
AU - Shah, Hiral
AU - Waters, Cheryl
AU - Winfield, Linda M.
AU - Beck, James C.
AU - Przedborski, Serge
AU - Fahn, Stanley
AU - Alcalay, Roy N.
N1 - Publisher Copyright:
© 2021, Springer-Verlag GmbH Germany, part of Springer Nature.
PY - 2022/3
Y1 - 2022/3
N2 - Background: With the explosion of COVID-19 globally, it was unclear if people with Parkinson’s disease (PD) were at increased risk for severe manifestations or negative outcomes. Objectives: To report on people with PD who had suspected or confirmed COVID-19 to understand how COVID-19 manifested in PD patients. Methods: We surveyed PD patients who reported COVID-19 to their Movement Disorders specialists at Columbia University Irving Medical Center and respondents from an online survey administered by the Parkinson’s Foundation that assessed COVID-19 symptoms, general clinical outcomes and changes in motor and non-motor PD symptoms. Results: Forty-six participants with PD and COVID-19 were enrolled. Similar to the general population, the manifestations of COVID-19 among people with PD were heterogeneous ranging from asymptomatic carriers (1/46) to death (6/46). The most commonly reported COVID-19 symptoms were fever/chills, fatigue, cough, weight loss, and muscle pain. Worsening and new onset of motor and non-motor PD symptoms during COVID-19 illness were also reported, including dyskinesia, rigidity, balance disturbances, anxiety, depression, and insomnia. Conclusion: We did not find sufficient evidence that PD is an independent risk factor for severe COVID-19 and death. Larger studies with controls are required to understand this further. Longitudinal follow-up of these participants will allow for observation of possible long-term effects of COVID-19 in PD patients.
AB - Background: With the explosion of COVID-19 globally, it was unclear if people with Parkinson’s disease (PD) were at increased risk for severe manifestations or negative outcomes. Objectives: To report on people with PD who had suspected or confirmed COVID-19 to understand how COVID-19 manifested in PD patients. Methods: We surveyed PD patients who reported COVID-19 to their Movement Disorders specialists at Columbia University Irving Medical Center and respondents from an online survey administered by the Parkinson’s Foundation that assessed COVID-19 symptoms, general clinical outcomes and changes in motor and non-motor PD symptoms. Results: Forty-six participants with PD and COVID-19 were enrolled. Similar to the general population, the manifestations of COVID-19 among people with PD were heterogeneous ranging from asymptomatic carriers (1/46) to death (6/46). The most commonly reported COVID-19 symptoms were fever/chills, fatigue, cough, weight loss, and muscle pain. Worsening and new onset of motor and non-motor PD symptoms during COVID-19 illness were also reported, including dyskinesia, rigidity, balance disturbances, anxiety, depression, and insomnia. Conclusion: We did not find sufficient evidence that PD is an independent risk factor for severe COVID-19 and death. Larger studies with controls are required to understand this further. Longitudinal follow-up of these participants will allow for observation of possible long-term effects of COVID-19 in PD patients.
KW - COVID-19
KW - Parkinson’s disease
UR - http://www.scopus.com/inward/record.url?scp=85114193831&partnerID=8YFLogxK
U2 - 10.1007/s00415-021-10784-3
DO - 10.1007/s00415-021-10784-3
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 34482434
AN - SCOPUS:85114193831
SN - 0340-5354
VL - 269
SP - 1107
EP - 1113
JO - Journal of Neurology
JF - Journal of Neurology
IS - 3
ER -